Dr Reddy's launches generic cholesterol-lowering drug in US

Dr Reddy's Laboratories today launched generic version of Pfizer's Caduet tablets, a cholesterol-lowering drug,

RELATED ARTICLES

in the American market after getting the approval from the US health regulator.

The company has launched Amlodipine Besylate and Atorvastatin Calcium Tablets in the US market following the approval by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement.

The company's product is the generic equivalent of Pfizer Inc's Caduet tablets, it added.

The Hyderabad-based firm's Amlodipine Besylate and Atorvastatin Calcium tablets are available in bottle counts of 30 and 90, the company said.

According to IMS Health sales data, Caduet tablets brand and generics had US sales of around USD 163 million for the most recent twelve months ending in January 2014.

Dr Reddy's Laboratories shares were trading at Rs 2,594 apiece on the BSE in afternoon trade, down 1.60 per cent from its previous close.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Copy the characters (respecting upper/lower case) from the image.

EDITORIAL OF THE DAY

  • India would have done well not to supress the 'Bofors interview'

    Bofors is one case that refuses to go away two-and-half decades after it grabbed public attention and became a byword for political corruption, claimi

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Varun Dutt

THE BLAME GAME

In decision-making, the fundamental attribution error (FAE), also known as ...

Zehra Naqvi

Dignity of labour is dignity of life

M Rafi Khan, a retired police IG, used to ...

Gautam Gupta

Retailers have it tough, thanks to e-commerce

For the past few months our focus has been on ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture